Newsroom

Sorted by: Latest

-

LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM

BENGALURU, India--(BUSINESS WIRE)--L&T Technology Services announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM....
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 27.01.2026 FXGB LN IE00BD5HBR05 37,992.00 GBP 748,977.68 27.110  ...
-

Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  Australia and New Zealand Banking Group Issue of EUR 1,250,000,000.00 Floating Rate Senior Unsecured Notes due 29 October 2027 series 2146 Tranche 1 MTN ISSUE NAME. Our Ref. MS3889 ISIN Code. XS2986720816 INTEREST AMT PER DENOM. CURRENCY CODE. EUR DAY BASIS. Actual/360 (A004) NUM OF DAYS. 90 INTEREST RATE. 2.519 PCT VALUE DATE. 29/04/2026 INTEREST PERIOD. 29/01/2026 TO 29/04/2026 EUR 1,000.00 IS EUR 6.3 POOL FACTOR. N/A...
-

Cadeler Signs Preferred Supplier Agreement for Foundation Installation in 2028

COPENHAGEN, Denmark--(BUSINESS WIRE)--Cadeler has signed an agreement for the transportation and installation of monopiles and transition pieces at a large offshore wind farm in Europe....
-

SFI Health™ EMEA Announces the Launch in Poland of Equazen® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults

LUGANO, Switzerland--(BUSINESS WIRE)--SFI Health™ EMEA to launch Equazen® Forte in Poland, a concentrated product formulation to help the cognitive performance for young adults and adults....
-

Next 15 Group plc UK Regulatory Announcement: Capital Markets Day

LONDON--(BUSINESS WIRE)--  28 January 2026 Next 15 Group plc (“Next 15” or the “Group”) Capital Markets Day Next 15 Group plc (“Next 15” or the “Group”), the data-led growth consultancy, will today host a Capital Markets Day for institutional investors and analysts that will be held in London at 2pm GMT. During the event, management will provide further detail on the Group’s new strategy and priorities, following the actions taken to date to simplify the business, resolve legacy issues and stre...
-

YOUNG & CO'S BREWERY PLC UK Regulatory Announcement: Transaction in Own Shares

LONDON--(BUSINESS WIRE)--  28 January 2026 YOUNG & CO.’S BREWERY, P.L.C. Transaction in own shares Young & Co.’s Brewery, P.L.C. (the “Company”) announces that on 27 January 2026, in accordance with the terms of its share buyback programme announced by the Company on 17 November 2025 (the “Share Buyback Programme”), it has purchased the following Non-voting ordinary shares of 12.5 pence each (“Non-voting Shares” and the “Purchased Shares”) in the Company through Peel Hunt LLP (“Peel Hun...
-

Pershing Square Holdings, Ltd. UK Regulatory Announcement: Transaction in Own Shares

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 27 January 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 27 January 2026 Number of Public Shares Purchased: 19...
-

Next 15 Group plc UK Regulatory Announcement: Trading Statement

LONDON--(BUSINESS WIRE)--  28 January 2026 Next 15 Group plc (“Next 15” or the “Group”) Full Year Trading Update Next 15 Group plc (“Next 15” or the “Group”), the data-led growth consultancy, today provides an update on trading for the financial year ending 31 January 2026 (“FY26”), ahead of its Capital Markets Day later today. FY26 performance is anticipated to be in-line with market expectations*, underpinned by robust trading results through the final weeks of 2025. We approach the conclusio...
-

Sensorion annonce un financement de 60 millions d’euros incluant un investissement stratégique de Sanofi de 20 millions d’euros aux côtés de spécialistes mondiaux de la santé afin de faire progresser son portefeuille de produits de thérapie génique

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), société pionnière de biotechnologie au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer, traiter et prévenir les troubles de la perte auditive, annonce aujourd'hui la réalisation d’une offre réservée à des catégories spécifiques d'investisseurs (l' « Offre Réservée ») d'un montant de 60 millions d'euros, à travers l'émission de 214 285 714 actions ordinaires nouvelles...